Latest news & insights
Professor Alan Boyd recognised in The Medicine Maker Power List 2025
Professor Alan Boyd, CEO of Boyds, has once again been recognised in the Advanced Medicine category of The Medicine Maker’s Power List, which celebrates pioneers driving progress and shaping the future of drug development.
Boyds expands US regulatory affairs team with new hire
We are delighted to announce the appointment of senior regulatory affairs professional, Kelsey Lenoch.
Boyds celebrates 20th anniversary milestone
Today (17 March 2025) marks the 20th anniversary of Boyds. From humble beginnings to becoming a key player in drug development consultancy, our story is one of innovation and growth, driven by a dedication to improving the lives of patients worldwide.
Laura Erwin joins Medical Writing Team
Boyds has welcomed Laura Erwin as Senior Clinical and Regulatory Medical Writer to the team bolstering Boyds’ regulatory writing expertise.
Boyds appoints Group Financial Controller
Boyds is delighted to announce the appointment of Muhammad Nadeem who has joined the company as Group Financial Controller.
UK to introduce world-first regulatory framework for manufacture of innovative medicines at the point of patient care
The UK is the first country to establish a dedicated regulatory framework for manufacturing innovative medicines at or near the point of patient care
Director promotion for regulatory affairs professional Dr Eric Hardter
Boyds is delighted to announce the promotion of Eric Hardter to Director of Regulatory Affairs.
Dr Katherine Bowen promoted to Vice President of Regulatory Affairs
Boyds is delighted to announce the appointment of Dr Katherine Bowen to Vice President of Regulatory Affairs. Katherine joined Boyds in 2022 as Senior Director
